Periodic follow-up of breast cancer patients is a common policy and specific programmes have been devised (Horton, 1984; Humphrey et al., 1982) . Nevertheless, routine tests for systemic disease have been criticised for being expensive and because no convincing evidence has been produced thus far of a favourable prognostic impact of early detection and treatment of distant metastases (Andreoli et al., 1987; Ciatto et al., 1985; Dewar & Kerr, 1985; Hughes & Courtney, 1985) .
Standard two-views chest X-ray (CXR) is commonly employed to detect intrathoracic metastases (ITM) to the lung, pleura or mediastinum which represents a relatively frequent pattern of first recurrence (Ciatto et al., 1985) .
The aim of the present report was to review a large series of patients undergoing periodic CXR survey and to assess the diagnostic and prognostic impact of this procedure. pathologic category (N -= not involved, N + = involved), the date of primary treatment and of ITM detection, the presence of subjective symptoms (A = asymptomatic.
S =symptomatic) related to ITM (cough, dyspnoea, thoracic pain) and worth further investigation, and final status. Asymptomatic cases were actually 'screen detected' being diagnosed on CXR at planned follow-up visits whereas symptomatic cases were 'interval' cases being diagnosed on CXR at self-referral because of subjective symptoms in the interval between two consecutive planned controls. Interval cases did always refer to the study centre at the time of recurrence.
The average disease-free interval and overall survival from primary treatment were evaluated according to the symptomatic status at ITM diagnosis. Survival curves were determined (Kaplan & Meyer, 1958) and the statistical difference between curves was calculated by the log rank test (Peto & Peto, 1972) .
A multivariate analysis of the correlations between prognosis and symptomatic status at ITM detection was carried out according to Cox's logistic regression model (Cox, 1972) RR is assumed to be I for reference categorical variables (N-,A).
sampling cannot be excluded. In fact, slow growing metastases are more likely to be detected as asymptomatic as they stay for a longer period in the phase of preclinical detectability. The same bias might account for the selection in the asymptomatic group of indolent cancers which are more likely to present a smaler volume of the disease at diagnosis and a higher probability of hormone sensitivity. Thus, because of length-biased sampling, a more favourable prognosis of A cases might be more or less totally ascribed to a selection of slow growing ITM more likely to respond to treatment. Actually, no survival difference was observed in this study. Length bias sampling probably occurred but this does not affect the implications of the final finding that early detection in the asymptomatic phase has no favourable prognostic impact. No therapeutic selection bias was detected as treatment was never delayed until symptoms onset in patients with asymptomatic ITM and the type of treatment was absolutely independent from symptomatic status.
In conclusion, according to the present experience periodic CXR survey of breast cancer patients allowed for early detection of ITM but it did not improve life expectancy. CXR survey seems to us a very questionable policy and its routine use should be carefully reconsidered.
